Rosalind Franklin University Helix 51 Saros $2M... - Oct 2

The Story

Rosalind Franklin University Helix 51 company Saros Therapeutics received its second National Cancer Institute Phase II award of approximately $2 million, the company announced from NORTH CHICAGO, Ill. on Oct. 2, 2026. The grant is intended to advance Saros's cancer immunotherapy work.

Why It Matters For Your Portfolio

• Approximately $2 million in additional funding, the second NCI Phase II award, provides tangible financial support for Saros's development program, which may extend its operational runway.
• The award is federal backing from the National Cancer Institute, which can increase program credibility and draw attention from biopharma partners and investors.
• Saros operates inside Rosalind Franklin University's Helix 51 biomedical incubator in North Chicago, highlighting RFU's role in fostering early-stage biotech innovation that could create deal flow in the cluster.
• Because this is a Phase II NCI award, it speaks to mid-stage clinical or translational progress for the program named in the release, which matters for future milestones and news flow.

The Trade

Who should watch: biotech and life-science investors tracking RFU's Helix 51 portfolio, venture observers, and partnership scouts. Monitor Saros Therapeutics announcements and any NCI progress updates for data or milestone news that could affect visibility and funding momentum. For informational purposes only, this note summarizes reported funding and does not recommend any specific investment action.